Introduction
============

With the growth of aging population, incidence of hip joint disease shows an increasing trend. Artificial hip replacement is a type of reconstructive operation that replaces the partial or integral damaged hip joint by adopting joint prosthesis fabricated by artificial simulation to ameliorate and restore the function of the hip joint, and is one of the major methods in the treatment of joint diseases in recent years ([@b1-etm-0-0-6661]--[@b3-etm-0-0-6661]).

Glutathione S transferases (GSTs) are an important family of phase II metabolic enzymes in the human body, and family members include GSTM1, GSTT1, and GSTP1 ([@b4-etm-0-0-6661],[@b5-etm-0-0-6661]). A previous study ([@b6-etm-0-0-6661]), showed that GSTs can catalyze the sulfhydryl group of reduced glutathione to react the electrophilic compound to increase their water solubility for excretion, so as to play an important role in detoxification of carcinogens and metabolism of anticancer drugs. Genetic polymorphisms of GSTs can alter enzyme activity, thus increasing the risk of various diseases ([@b6-etm-0-0-6661]). A previous study ([@b7-etm-0-0-6661]) has shown that the missing genotypes of GSTM1 and GSTT1 can lead to loss of function of their encoded enzymes. Alteration of A313G (Ile105Val) on exon 5 of GSTP1 (rs1695) results in decreased thermal stability and reduced specific catalytic activity of the encoded protein. Changes in the polymorphisms of the three genes can affect the metabolism of chemotherapeutic drugs by the cells, resulting in differences in the effective plasma concentrations of chemotherapeutic agents, which ultimately leads to differences in efficacy, toxicity, and prognosis of chemotherapy ([@b8-etm-0-0-6661]). Currently, GSTs gene polymorphism has attracted more and more attentions. Previous studies have shown that glutathione S-transferase M1 (GSTM1) deletion may lead to the occurrence of some malignant tumors, such as lung cancer ([@b9-etm-0-0-6661]), liver cancer ([@b10-etm-0-0-6661]), gastric cancer ([@b11-etm-0-0-6661]) and nasopharyngeal carcinoma ([@b12-etm-0-0-6661]) and other tumors. A previous study ([@b13-etm-0-0-6661]), has reported that GSTs gene polymorphisms may lead to reduced antioxidant activity of enzymes, leading to increased susceptibility to diabetes. Another study showed that infection rate of diabetic patients is 3 times higher than that of non-diabetic patients after artificial hip replacement ([@b14-etm-0-0-6661]). However, the correlations between GSTM1 gene deletion and artificial hip replacement are still controversial. Hence, the present study investigated the correlation between GSTM1 gene deletion and recovery of patients undergoing artificial hip replacement.

Materials and methods
=====================

### Basic data

A total of 241 patients who received artificial hip replacement in People\'s Hospital of Rizhao from December 2010 to October 2016 were enrolled to serve as observation group. Those patients included 149 males (61.8%) and 92 (38.9%) females, and the mean age was 65±9.41 years. Eighty healthy people who at the same period took physical examination in our hospital were selected to serve as control group. Control group included 41 males (51.25%) and 39 females (48.75%). There were no statistically significant differences in sex, age, hypertension, diabetes and smoking history between two groups (P\>0.05) ([Table I](#tI-etm-0-0-6661){ref-type="table"}). Harris scoring ([@b15-etm-0-0-6661]), which includes seven indexes: Pain (44 points), daily activity (14 points), gait (11 points), walking aid (11 points), walking distance (11 points), deformity (4 points) and the degree of activity (5 points) was performed with a total of 100 points. Four grades were set based on the total scores: 100-90, excellent; 89--80, good; 79--70, fair; \<70, poor. All participants and their families signed informed consent. This study was approved by the Ethics Committee of People\'s Hospital of Rizhao (Shandong, China).

### Instrument and reagents

TRIzol reagent and PCR 2X Taq MasterMix kit was purchased from Invitrogen; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). DNA Marker was purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). Roche light cycle 480 was purchased from Roche Diagnostics (Basel, Switzerland).

### Follow-up

Patients were followed up once every month within the first three months after operation, followed by once every three months for nine months. Hospitalization time, the length of the use of antibiotics and the condition of infection were analyzed in deletion group and non-deletion group were recorded. After discharge from hospital, the patient continued to receive antithrombotic therapy, such as oral coumarin or aspirin, and the corresponding training, such as the constriction exercise of the affected limb, the continuous passive exercise, the training of joint motion, walking practice and stairs exercises were used to prevent postoperative complications.

### Exclusion and inclusion criteria

Inclusion criteria: Patients received no hormone drug treatments; patients with normal liver and kidney function; patients willing to cooperate with researchers. Exclusion: Patients with rheumatism, rheumatoid arthritis or gonarthritis; patients with mental illness or physical disability; patients who were not willing to receive treatment.

### Collection of specimens and extraction of total ribonucleic acid (RNA)

Three milliliters synovial fluid was collected and transferred into a centrifuge tube, followed by centrifugation at 2,500 × g at 4°C for 10 min. Subsequently, the supernatant was transferred to a Eppendorf (EP) tube and restored at −80°C. DNA was extracted according to the instructions of kit, followed by reservation at −20°C.

### Single nucleotide polymorphism sequencing

GSTM1 genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with β-globin as the endogenous control. Primer sequence of GSTM1 gene were: 5′-TACTCAGAGTTTCTGGGGAAGCGGC-3′ (forward) and 5′-ACGGTGGAGGTCAAGGACATCATAG-3′ (reverse); Primer sequences of endogenous control β-globin were: 5′-GAACCCCAGGGTACAGAGAAAGATC-3′ (forward) and 5′-GGACGAAGGAAGAGTGTCGGAAG-3′ (reverse). PCR reaction system was 25 µl: 2 µl DNA template, 0.5 mol/l primer, 2×2.0 µl deoxy-ribonucleoside triphosphate (dNTP), 2.5 µl buffer, 1.5 mol/l MgCl~2~ and 1.0 IU TaqDNA. PCR reaction conditions were: Pre-denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 45 sec, 55°C for 50 sec and 72°C for 50 sec, and 72°C for 5 min. Finally, 10 ul PCR product was subjected to electrophoresis by using 1.5% agarose gel for 45 min, followed by staining with 1.5% ethidium bromide (EB).

### Statistical analysis

Data obtained in the present study were analyzed by using Statistical Product and Service Solutions (SPSS, Inc., Chicago, IL, USA) v.17.0 statistical software. Enumeration data were compared by Chi-square test. Measurement data were expressed by mean ± SD. t-test was used for the comparisons between deletion and non-deletion groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### PCR amplification results

Multiplex PCR amplification of GSTM1 was carried to obtain products with a length of 298, 248 and 207 bp. GSTMl (−) genotype only showed a band of 298 bp, while GSTM1 (+) showed two bands after electrophoresis ([Fig. 1](#f1-etm-0-0-6661){ref-type="fig"}).

### GSTM1 gene polymorphism and recovery of patients undergoing artificial hip replacement

In the present study, there were 241 patients with artificial hip joint replacement. Giscontinuous chi-square test showed that GSTM1 gene deletion type in observation group (67.63%) was higher than that in control group (41.25%), suggesting that deletion of GSTM1 gene is related to the poor recovery of patients undergoing artificial hip replacement (OR=1.51, 95% CI: 1.075--2.023, P\<0.05; [Table II](#tII-etm-0-0-6661){ref-type="table"}).

### Comparison of clinical data between deletion group and non-deletion group in experimental group

Patients were divided into GSTM1-deletion and non-GSTM1-deletion groups. we found that there was no difference in sex, age, hypertension, smoking history, leukocyte, hemoglobin, platelet, and BMI index between patients in deletion and non-deletion groups (P\>0.05), The number of patients with diabetes in GSTM1-deletion was more than that in non-GSTM1-deletion group (P\<0.05; [Table III](#tIII-etm-0-0-6661){ref-type="table"}).

### Prognosis of patients

Hospitalization time and the length of the use of antibiotics were compared between deletion group and non-deletion group. We found that hospitalization time and the length of the use of antibiotics were significantly longer in deletion group than in non-deletion group (P\<0.05; [Fig. 2](#f2-etm-0-0-6661){ref-type="fig"}). In addition, infection rate of deletion group was significantly higher than that of non-deletion group (P\<0.05; [Table IV](#tIV-etm-0-0-6661){ref-type="table"}).

### Follow-up

Observation group was divided in two groups including deletion group and non-deletion group, and all patients were followed up for 12 months. Harris scoring was performed. No significant differences in Harris scores were found between two groups on the day of discharge (P\>0.05). Harris scores were significantly lower in deletion group than those in non-deletion group half year (P=0.004) and one year after discharge (P=0.001; [Table V](#tV-etm-0-0-6661){ref-type="table"}).

Discussion
==========

In recent years, with the application of biological materials and maturation of surgical techniques, artificial hip replacement technique becomes more and more mature ([@b16-etm-0-0-6661],[@b17-etm-0-0-6661]). At present, postoperative infection is still the main problem of artificial hip replacement, and has a great influence on the recovery of patients ([@b18-etm-0-0-6661]). Hence, in order to reduce postoperative complications caused by artificial hip replacement and improve patient\'s quality of life, effects of GSTM1 polymorphism on the recovery of patients underwent artificial hip replacement was first investigated in the present study.

As an important phase II metabolic enzyme, GSTM1 is located on the first chromosome, which has detoxificative and cell protective effects to the human body ([@b19-etm-0-0-6661],[@b20-etm-0-0-6661]). A large number of studies reported that ([@b21-etm-0-0-6661]--[@b23-etm-0-0-6661]) GSTM1 is associated with the occurrence and prognosis of various types of cancer, but its involvement in artificial hip replacement remains unclear. In the present study, PCR-RFLP technology was adopted to analyze the genotype deletion of GSTM1 gene, so as to study the recovery of patients undergoing artificial hip replacement.

Results of this study indicated that the distribution frequency of deletion type of GSTM1 gene was 41.25% in control group, which is consistent with the finding in previous study ([@b24-etm-0-0-6661]). Among 241 patients undergoing artificial hip replacement, there were 163 (67.63%) cases of deletion type of GSTM1 gene. Significant difference in distribution frequency was found between observation group and control group (OR=1.51, 95% CI: 1.075--2.023, P\<0.05), suggesting that deletion of GSTM1 gene is correlated with poor recovery. Studies have shown that the absence of the GSTM1 gene may lead to the development of diabetes, and the incidence of infection in patients with diabetes after hip replacement is much higher than normal, delaying recovery and leading to poor prognosi. We compared the clinical data between the deletion group and the non-deletion group. We found that the number patients with diabetes in deletion group were significantly bigger than that in the non-deletion group. This also shows that there is a link between the loss of GSTM1 gene and the prognosis of hip replacement patients. Loss of GSTM1 gene may cause the development of diabetes, and the risk of infection in patients with diabetes after hip replacement is much higher than that in normal people. Therefore, patients were further divided into GSTM1 gene deletion group and GSTM1 gene non-deletion group for follow-up study. Harris score revealed that recovery of patients in GSTM1 gene deletion group was significantly worse compared with that in GSTM1 gene non-deletion group within one year after discharge (P\<0.05), indicating that GSTM1 gene deletion may be a risk factor for the delayed recovery in patients underwent artificial hip replacement. Those results indicate that GSTM1 gene deletion in patients with hip replacement had an impact on prognosis. Life safety and health issues are currently the focus of social attention. Recovery after artificial hip replacement is a slow and systematic process. Individualized treatment and rehabilitation can reduce the occurrence of complications after replacement, thus achieving better recovery effect to improve the quality of life of patients. This study provided references for the prediction of recovery of patients with artificial hip replacement.

It is the first time to make study through combining GSTM1 gene with artificial hip replacement. This study is hoped to provide better service for the recovery of patients and clinical treatment through discussing the relationship between GSTM1 gene and recovery of patients undergoing artificial hip replacement. Also an in-depth discussion will be made according to the results of this study and deeper-seated experiments will be designed according to the guess of influence mechanism in the future. There are also limitations in this study, for example, the short period of the follow-up and small sample size caused by the difficulty in enrolling healthy volunteers, in which may affects the reliability of the results. Future studies with bigger sample size are needed to further confirm the conclusions in the present study.

In conclusion, PCR-RFLP technology is successfully utilized to analyze GSTM1 genotypes in synovial fluid, and the results suggest that GSTM1 gene polymorphism is correlated with recovery of patients undergoing artificial hip replacement. The present study provided references for postoperative rehabilitation of patients undergoing artificial hip replacement.
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###### 

Basic data of two groups.

  Factor                       Experimental group (%)   Control group (%)   OR (95% CI)         χ^2^    P-value
  ---------------------------- ------------------------ ------------------- ------------------- ------- ---------
  Sex                                                                                                   
    Male                       149 (61.8)               41 (51.25)          1.51 (1.12--4.94)   0.814   0.574
    Female                     92 (38.9)                39 (48.75)                                      
  Age (years)                                                                                           
    ≥65                        107 (44.39)              37 (46.25)          2.41 (1.71--3.44)   6.74    0.749
    \<60                       134 (55.61)              43 (53.75)                                      
  Hypertension                                                                                          
    Yes                        170 (70.53)              33 (41.25)                                      
    No                         71 (29.47)               47 (58.75)                                      
  Diabetes                                                                                              
    Yes                        96 (39.83)               29 (36.25)          1.88 (1.08--2.98)   5.41    0.766
    No                         145 (60.17)              51 (63.75)                                      
  Smoking history                                                                                       
    Yes                        162 (67.21)              41 (51.25)          2.87 (1.74--3.04)   10.55   0.648
    No                         79 (32.79)               39 (48.75)                                      
  White blood cells (10×9/l)   4.49±1.5                 4.1±1.7                                 1.948   0.052
  Hemoglobin (g/l)             162.5±26.40              169.6±33.00                             1.485   0.138
  Platelets (10×9/l)           132.0±25.14              138.0±25.20                             1.849   0.065
  BMI index (kg/m^3^)          22.51±1.30               22.78±1.15                              1.655   0.099

###### 

GSTM1 gene polymorphism and recovery of patients undergoing artificial hip replacement.

  Genotype      Experimental group, n=241 (%)   Control group, n=80 (%)   OR (95% CI)           χ^2^    P-value
  ------------- ------------------------------- ------------------------- --------------------- ------- ---------
  GSTM1                                                                                                 
    GSTM1 (+)     78 (32.37)                    47 (58.75)                --                            
    GSTM1 (−)   163 (67.63)                     33 (41.25)                1.51 (1.075--2.023)   0.743   \<0.05

###### 

Comparison of clinical data between deletion group and non-deletion group in experimental group.

  Variables                    Deletion (n=163)   Non-deletion (n=78)   t       P-value
  ---------------------------- ------------------ --------------------- ------- ---------
  Sex                                                                           
    Male                       100                49                            0.887
    Female                     63                 29                            
  Age (years)                                                                   
    ≥65                        75                 32                            0.491
    \<65                       88                 46                            
  Hypertension                                                                  
    Yes                        120                50                            0.134
    No                         43                 28                            
  Diabetes                                                                      
    Yes                        77                 19                            0.001
    No                         86                 59                            
  Smoking history                                                               
    Yes                        115                47                            0.142
    No                         48                 31                            
  White blood cells (10×9/l)   4.84±1.76          4.61±1.24             1.037   0.301
  Hemoglobin (g/l)             163.39±23.87       167.39±25.75          1.186   0.237
  Platelet (10×9/l)            126.89±29.12       134.29±29.61          1.836   0.068
  BMI index (kg/m^3^)          22.48±1.84         22.89±1.06            1.827   0.069

###### 

Prognosis of patients.

  Groups                 Infection    Non-infection   P-value
  ---------------------- ------------ --------------- ---------
  Deletion (n=78)        37 (47.44)   41 (52.56)      0.048
  Non-deletion (n=163)   55 (33.74)   108 (66.26)     

###### 

Comparisons of Harris scores.

  Group                          n     Discharge after operation   Half a year after discharge   One year after discharge
  ------------------------------ ----- --------------------------- ----------------------------- --------------------------
  GSTM1 gene deletion type       163   59.41±12.88                 66.47±10.57                   71.43±16.94
  GSTM1 gene non-deletion type   78    60.57±14.38                 70.76±11.67                   79.12±15.51
  t value                              6.874                       8.419                         9.354
  P-value                              0.364                       0.074                         0.047
